Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats
- PMID: 24909673
- DOI: 10.1016/j.bbr.2014.05.065
Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats
Abstract
Ketamine, a non-competitive N-methyl-d-aspartate receptor antagonist, and group II metabotropic glutamate (mGlu2/3) receptor antagonists produce antidepressant effects in animal models of depression, which last for at least 24h, through the transient increase in glutamate release, leading to activation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) receptor. Both ketamine and an mGlu2/3 receptor antagonist reportedly increase the expression of GluR1, an AMPA receptor subunit, within 24h, which may account for the sustained enhancement of excitatory synaptic transmission following ketamine administration. However, whether the sustained increase in AMPA receptor-mediated synaptic transmission is associated with the antidepressant effects of ketamine and mGlu2/3 receptor antagonists has not yet been investigated. In the present study, to address this question, we tested whether AMPA receptor stimulation at 24h after a single injection of ketamine or an mGlu2/3 receptor antagonist, (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl)propanoic acid (LY341495) was necessary for the antidepressant effect of these compounds using a forced swim test in rats. A single injection of ketamine or LY341495 at 24h before the test significantly decreased the immobility time. An AMPA receptor antagonist, 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX), administered 30min prior to the test significantly and dose-dependently reversed the antidepressant effects of ketamine and LY341495, while NBQX itself had no effect on the immobility time. Our findings suggest that AMPA receptor stimulation at 24h after a single injection of ketamine or LY341495 is required to produce the anti-immobility effects of these compounds. Moreover, the present results provide additional evidence that an mGlu2/3 receptor antagonist may share some of neural mechanisms with ketamine to exert antidepressant effects.
Keywords: AMPA receptor; Forced swim test; Ketamine; LY341495; mGlu2/3 receptor.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test.Psychopharmacology (Berl). 2014 Jun;231(11):2291-8. doi: 10.1007/s00213-013-3378-0. Epub 2014 Jan 9. Psychopharmacology (Berl). 2014. PMID: 24402133
-
The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.J Pharmacol Exp Ther. 2016 Jul;358(1):71-82. doi: 10.1124/jpet.116.233627. Epub 2016 May 12. J Pharmacol Exp Ther. 2016. PMID: 27189960
-
Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats.Behav Pharmacol. 2019 Sep;30(6):471-477. doi: 10.1097/FBP.0000000000000471. Behav Pharmacol. 2019. PMID: 30724804
-
[The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Aug;32(4):219-26. Nihon Shinkei Seishin Yakurigaku Zasshi. 2012. PMID: 23012890 Review. Japanese.
-
Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.Int J Mol Sci. 2019 Mar 13;20(6):1270. doi: 10.3390/ijms20061270. Int J Mol Sci. 2019. PMID: 30871246 Free PMC article. Review.
Cited by
-
The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus.Ups J Med Sci. 2015;120(4):241-8. doi: 10.3109/03009734.2015.1060281. Epub 2015 Jul 28. Ups J Med Sci. 2015. PMID: 26220286 Free PMC article.
-
Ketamine's rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors.Elife. 2023 Jun 26;12:e86022. doi: 10.7554/eLife.86022. Elife. 2023. PMID: 37358072 Free PMC article.
-
Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGlu3) impairs postsynaptic plasticity and modulates affective behaviors.Neuropsychopharmacology. 2021 Nov;46(12):2148-2157. doi: 10.1038/s41386-021-01041-2. Epub 2021 May 25. Neuropsychopharmacology. 2021. PMID: 34035469 Free PMC article.
-
Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation.Curr Neuropharmacol. 2018 Mar 5;16(3):297-307. doi: 10.2174/1570159X15666170630164715. Curr Neuropharmacol. 2018. PMID: 28676011 Free PMC article. Review.
-
Ketamine and the Future of Rapid-Acting Antidepressants.Annu Rev Clin Psychol. 2021 May 7;17:207-231. doi: 10.1146/annurev-clinpsy-072120-014126. Epub 2021 Feb 9. Annu Rev Clin Psychol. 2021. PMID: 33561364 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
